Chinese Hepatolgy ›› 2022, Vol. 27 ›› Issue (5): 553-556.

• Viral Hepatitis • Previous Articles     Next Articles

Effect of comorbid type 2 diabetes mellitus on the antiviral response of interferon combined with ribavirin in patients with chronic hepatitis C

HU Chun-xia1,YANG Jiao-nan2, ZHANG Feng-xiao1, HU Jing-hua1   

  1. 1. Department of Infection, Zhoukou Central Hospital, Henan 460000, China;
    2. Department of Gastroenterology, Zhengzhou people′s Hospital, Henan 450003, China
  • Received:2021-10-30 Online:2022-05-31 Published:2022-07-13

PDF (PC)

210

Abstract: Objective To explore the effect of comorbid type 2 diabetes mellitus (T2DM) on the antiviral response of interferon combined with ribavirin in the treatment of chronic hepatitis C (CHC) patients. Methods 78 CHC patients with T2DM (study group) and 53 patients with CHC alone (control group) were diagnosed and treated between March 2017 and June 2019. All patients were treated with interferon in combination with ribavirin for 48 weeks and followed up for 24 weeks after the treatment. Indexes of liver and pancreatic islet functions were tested before and after the treatment. The antiviral responses of the two groups of patients were compared, and drug safety was evaluated. Results The liver function indexes of both groups were significantly improved after treatment. There was no statistically significant difference in the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL) between the two groups (P>0.05). The fasting blood glucose (FPG) level of the study group was (5.82±1.03) mmol/L, and the insulin resistance index (HOMA-IR) was (2.43±0.40) after treatment, which was higher than those of (5.24±0.91) mol/L and (1.91±0.34) respectively in the control group, the difference was statistically significant (P<0.05). There was no significant difference in rapid virological response (RVR) and early virological response (EVR) between the two groups of patients after treatment (P>0.05). However, the virological response at the end of treatment (ETVR) and sustained virological response (SVR) of the study group were 52.56% and 46.15%, respectively, which were lower than those of 71.70% and 66.04% in the control group, the difference was statistically significant (P<0.05). The incidence of total adverse drug reactions of the study group and the control group during the treatment period were 8.97% and 7.55%, respectively, without statistically difference (P>0.05). Conclusion Antiviral therapy with Interferon in combination with ribavirin can improve liver and pancreatic islet functions in CHC patients with good safety, but comorbid T2DM may affect the virological response of the antiviral theatment.

Key words: Type 2 diabetes, Chronic hepatitis C, Liver function, Pancreatic islet function, Antiviral response